SCHEMBL16232170

SCHEMBL16232170

CC(C(=O)O)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.50
MMP9 P14780 3/20 0.50
MMP1 P03956 2/20 0.50
MMP13 P45452 2/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
MMP8 P22894 1/20 0.47
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
KCNH2 Q12809 2/20 0.43
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
PSEN1 P49768 2/20 0.41
PSEN2 P49810 2/20 0.41
APH1B Q8WW43 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16232171 0.83 PSEN1 (0.44) MMP2MMP9MMP1MMP13MMP3
SCHEMBL22206134 0.82 CA1 (0.54) MMP2MMP9MMP1MMP13MMP3
SCHEMBL28230363 0.82 CA1 (0.54) MMP2MMP9MMP1MMP13MMP3
SCHEMBL1200588 0.82 CA1 (0.53) MMP2MMP9MMP1MMP13MMP7
SCHEMBL8013573 0.81 MMP2 (0.55) MMP2MMP9MMP1MMP13MMP3
SCHEMBL1464399 0.80 MMP1 (0.54) MMP2MMP9MMP1MMP13MMP3
SCHEMBL1980896 0.80 SLC1A3 (0.51) MMP2MMP9MMP1MMP13MMP3
SCHEMBL6470795 0.79 SLC1A3 (0.49) CA1CA2SLC1A3SLC1A2SLC1A1
SCHEMBL23049688 0.78 CA2 (0.48) MMP2MMP9CA1CA2CA12
SCHEMBL23049767 0.78 CA2 (0.48) MMP2MMP9CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007639-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2026-01-08 US disclosed
US-12440477-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2025-10-14 US disclosed
US-11730714-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-08-22 US disclosed
US-11730714-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-08-22 US disclosed
US-11591284-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-02-28 US disclosed
US-11147788-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2021-10-19 US disclosed
CN-107820425-B Compounds for the treatment of neuromuscular disorders NMD制药股份公司 2021-08-31 CN disclosed
EP-3307262-B1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA AS (DK) 2021-05-19 EP disclosed
EP-3307262-B1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA AS (DK) 2021-05-19 EP disclosed
US-10934244-B2 Compounds for use in treating neuromuscular disorders NMD PHARMA A/S (DK) 2021-03-02 US disclosed
EP-3307262-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD Pharma ApS (DK) 2018-04-18 EP disclosed
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2018-04-12 US disclosed
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2018-04-12 US disclosed
CN-107820425-A For treating the compound of neuromuscular disorder NMD制药公司 2018-03-20 CN disclosed
WO-2016202341-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2016-12-22 WO disclosed
WO-2016202341-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2016-12-22 WO disclosed
US-20150299184-A1 Amine Derivatives as Potassium Channel Blockers BIONOMICS LIMITED (AU) 2015-10-22 US disclosed
US-20150299184-A1 Amine Derivatives as Potassium Channel Blockers BIONOMICS LIMITED (AU) 2015-10-22 US disclosed
US-20140336198-A1 Amine Derivatives as Potassium Channel Blockers MERCK PATENT GMBH (DE) 2014-11-13 US disclosed
US-20140336198-A1 Amine Derivatives as Potassium Channel Blockers MERCK PATENT GMBH (DE) 2014-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730714-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885
US-10934244-B2 Compounds for use in treating neuromuscular disorders CPT1B, CLCN2, TNNC1 MMP2 3144/4885MMP9 2977/4885MMP1 1299/4885
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS CPT1B, CLCN2, TNNC1 MMP2 3144/4885MMP9 2977/4885MMP1 1299/4885
US-11147788-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885
US-12440477-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885
US-11591284-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, CACNA1S MMP2 4455/4885MMP9 4489/4885MMP1 929/4885
US-20140336198-A1 Amine Derivatives as Potassium Channel Blockers KCNA3, KCNH3, KCNK3 MMP2 4243/4885MMP9 2830/4885MMP1 3792/4885
US-20260007639-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS RYR1, CLIC1, RYR2 MMP2 4293/4885MMP9 4249/4885MMP1 1853/4885
US-20150299184-A1 Amine Derivatives as Potassium Channel Blockers KCNA3, KCNH3, KCNK3 MMP2 4243/4885MMP9 2830/4885MMP1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.